Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable

Epidemiology

Volumn 17, Issue 3, 2006, Pages 268-275

  Brookhart, M Alan ^a   Wang, Philip S ^a   Solomon, Daniel H ^a   Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GASTROINTESTINAL TRACT; HUMANS; MALE; PENNSYLVANIA; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; TREATMENT OUTCOME;

EID: 33646802964     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ede.0000193606.58671.c5     Document Type: Article

References (40)

1. Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Knopf; 2004.
2. Jick H. The discovery of drug-induced illness. N Engl J Med. 1977;296:481-485.
3. Risk assessment of drugs, biologies and therapeutic devices: present and future issues. Pharmacoepidemiol Drug Saf. 2003;12:653-662.
4. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323-337.
5. Walker AM. Confounding by indication. Epidemiology. 1996;7:335-336.
6. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet. 2004;363:1728-1731.
7. Strom BL, Miettinen OS, Melmon KL. Post-marketing studies of drug efficacy: how? Am J Med. 1984;77:703-708.
8. Miettinen OS. The need for randomization in the study of intended effects. Stat Med. 1983;2:267-271.
9. Walker AM, Stampfer MJ. Observational studies of drug safety. Lancet. 1996;348:489.
10. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet. 2001;357:455-462.
11. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10:577-581.
12. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med. 1995;123:888-889.
13. MacDonald TM, Morant SV, Goldstein JL, et al. Channeling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut. 2003;52:1265-1270.
14. McMahon AD, MacDonald TM. Design issues for drug epidemiology. Br J Clin Pharmacol. 2000;50:419-425.
15. Wen SW, Kramer MS. Uses of ecologic studies in the assessment of intended treatment effects. J Clin Epidemiol. 1999;52:7-12.
16. Joffe MM. Confounding by indication: the case of calcium channel blockers. Pharmacoepidemiol Drug Saf. 2000;9:37-41.
17. Johnston SC. Combining ecological and individual variables to reduce confounding by indication: case study - subarachnoid hemorrhage treatment. J Clin Epidemiol. 2000;53:1236-1241.
18. Johnston SC, Henneman T, McCulloch CE, et al. Modeling treatment effects on binary outcomes with grouped-treatment variables and individual covariates. Am J Epidemiol. 2002;156:753-760.
19. Brooks JM, Chrischilles EA, Scott SD, et al. Was breast conserving surgery underutilized for early stage breast cancer? Instrumental variables evidence for stage II patients from Iowa [erratum appears in Health Serv Res. 2004;39:693]. Health Serv Res. 2003;38:1385-1402.
20. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA. 1994;272:859-866.
21. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf. 2003;12:551-558.
22. Korn EL, Baumrind S. Clinician preference and the estimation of causal treatment effects. Stat Sci. 1998;13:209-235.
23. Solomon DH, Schneeweiss S, Glynn RJ, et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003;115:715-720.
24. Schneeweiss S, Glynn RJ, Avorn J, et al. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005;58:98-102.
25. Sebaldt RJ, Petrie A, Goldsmith CH, et al. Appropriateness of NSAID and coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study. Am J Manag Care. 2004;10:742-750.
26. Patino FG, Allison J, Olivieri J, et al. The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs. Arthritis Rheum. 2003;49:293-299.
27. Fowles JB, Lawthers AG, Weiner JP, et al. Agreement between physicians' office records and Medicare Part B claims data. Health Care Financ Rev. 1995;16:189-199.
28. Romano PS, Mark DH. Bias in the coding of hospital discharge data and its implications for quality assessment. Med Care. 1994;32:81-90.
29. Glynn RJ, Monane M, Gurwitz JH, et al. Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly. Am J Epidemiol. 1999;149:541-549.
30. Fisher ES, Whaley FS, Krushat WM, et al. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health. 1992;82:243-248.
31. Schneeweiss S, Glynn RJ, Tsai EH, et al. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005;16:17-24.
32. Baldwin LM, Adamache W, Klabunde CN, et al. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002;40(suppl):IV-82-95.
33. Raiford DS, Perez Gutthann S, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology. 1996;7:101-104.
34. Cattaruzzi C, Troncon MG, Agostinis L, et al. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol. 1999;52:499-502.
35. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29:722-729.
36. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17-34.
37. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc. 1996;81:444-455.
38. Rubin DB. Estimating causal effects of treatment in randomized and nonrandomized studies. J Educ Psychol. 1974;66:688-701.
39. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
40. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.